drugset / Trial / NCT02559778
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Phase 2
Recruiting
500 enrolled
Giselle Sholler
Beat NB Cancer Foundation · collabDell, Inc. · collabK C Pharmaceuticals Inc. · collabTeam Parker for Life · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Newly Diagnosed High-Risk Neuroblastoma.
Timeline
- Start
- 2015-09
- Primary completion
- 2030-09
- Completion
- 2035-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ceritinib | Small molecule | — | — |
| Comparator | Eflornithine | Small molecule | — | — |
| Comparator | Sorafenib | Small molecule | — | — |
| Comparator | Vorinostat | Small molecule | — | — |
| Comparator | dasatinib anhydrous | Small molecule | — | — |